However, further research has shown that only co-targeting of BCL2 and MCL1 is effective in AML cell lines with intrinsic or acquired resistance to BH3 mimetics or engineered to genetically overexpress BCL2 or BCL2A1 or downregulate BAX. The gene discussed is BAX; the disease is acute myeloid leukemia.